Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN - Free Report) had its target price reduced by JPMorgan Chase & Co. from $10.00 to $9.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other analysts also recently commented on the company. Oppenheimer started coverage on Dyne Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price on the stock. Guggenheim restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Jones Trading assumed coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 price target for the company. Robert W. Baird dropped their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research note on Wednesday, June 18th. Finally, Evercore ISI restated an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.63.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock traded down $0.38 during trading hours on Tuesday, hitting $9.02. The company's stock had a trading volume of 1,578,701 shares, compared to its average volume of 1,917,457. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The firm has a fifty day moving average of $11.19 and a 200-day moving average of $12.30. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -2.51 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, sell-side analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO John Cox purchased 100,000 shares of the stock in a transaction on Monday, July 14th. The shares were acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the transaction, the chief executive officer directly owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 14.14% of the company's stock.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth $2,340,000. Schroder Investment Management Group boosted its holdings in shares of Dyne Therapeutics by 63.3% during the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock valued at $3,477,000 after purchasing an additional 56,961 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Dyne Therapeutics by 4.2% during the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after purchasing an additional 5,383 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after acquiring an additional 13,677 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Dyne Therapeutics by 3.3% in the 4th quarter. Swiss National Bank now owns 108,600 shares of the company's stock valued at $2,559,000 after acquiring an additional 3,500 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.